Fig. 1 At the center is the rheumatologist. Often it is artistic work to juggle with antirheumatoid drugs. Sometimes a drug fails or the whole show ends up as a complete…
(1) where = absorbed dose rate to a target region of interest (Gy/sec or rad/hr) A S = activity (MBq or μCi) in source region S y i = number of radiations…
Fig. 1 Well-differentiated neuroendocrine tumor (NET) of pancreatic tail, s.p. extended pancreatectomy and partial omentectomy, initial tumor stage (UICC) pT2 (Ø 3.2 cm) pN1 (6/12) cM1 R0, LX VX, G2, proliferation rate…
(1) Since lethal lesions are Poisson-distributed across a cell population, the probability that a large population of cells will undergo a certain number of lethal lesions (i.e., the surviving fraction,…
Fig. 1 2D representation of the CD20 antigen (previously known as “B1”). Note that antibodies used in RIT bind to the extracellular domain. This figure was published in American Journal…
Fig. 1 Scheme of particle distribution in tissues. Shown are several electrons and an alpha particle. Clearly, total energy absorbed per unit mass, i.e., dose correlates with the number of particles…
Fig. 1 A schematic comparison of energy types for therapeutic radionuclides (Srivastava 2012) In general, all high-LET emitters are much more effective for small lesions and for micrometastatic disease. For example,…
Fig. 1 Publications describing rhenium-188 radiopharmaceutical development and clinical trials (data from MedLine) From a clinical perspective, radionuclide therapy has a high impact in the treatment of benign diseases, such as…
Global N = 206 Group under analysis All grades Grade 4 Radiation pneumonitis 206 treatments 1 (0.4 %) 0 GI ulcers 215 procedures 3 (1.4 %) 0 REILD (global) 206 treatments 24 (11 %)…
Type of disease Strategy Goal Single spots “rule of five” <5 cm diameter; <5 spots RFTA, (LITT), MW Complete destruction A0-ablation/curation Small hypervascularized lesion TAE with embozene; alternative: DC-Beads Complete destruction/curation Big…
